§ 01 What Is Melanotan 1?

Melanotan 1 (MT-1), also known as afamelanotide, is a synthetic linear analog of alpha-melanocyte-stimulating hormone (α-MSH). It is a 13-amino acid peptide designed to mimic and extend the biological activity of endogenous α-MSH at melanocortin receptors — particularly the melanocortin 1 receptor (MC1R), which is primarily expressed on melanocytes in the skin.

Melanotan 1 was originally developed in the 1980s at the University of Arizona by researchers studying melanocortin biology and its downstream effects on pigmentation. The compound was engineered to be a more potent and longer-lasting analog than naturally occurring α-MSH, which has a very short half-life in circulation due to rapid enzymatic degradation.

In research contexts, Melanotan 1 peptide is studied as a pharmacological tool for investigating MC1R biology, eumelanin synthesis pathways, photoprotection mechanisms in cell models, and systemic inflammatory signaling — all within in vitro and controlled research settings.

§ 02 Molecular Structure & Properties

The structure of Melanotan 1 is defined by its 13-amino acid sequence, which mirrors that of naturally occurring α-MSH with key substitutions that enhance receptor affinity and metabolic stability. The natural α-MSH sequence is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂ (13 residues).

MT-1 (afamelanotide) is a Nle⁴, D-Phe⁷ analog of α-MSH, meaning it incorporates two key amino acid substitutions relative to the natural sequence:

• Position 4 — Norleucine (Nle) substitution: Methionine at position 4 is replaced with norleucine, a non-natural amino acid. This modification eliminates oxidation of the methionine sulfur, significantly improving the compound’s chemical stability during synthesis, storage, and in aqueous solution.
• Position 7 — D-Phenylalanine (D-Phe) substitution: The L-phenylalanine at position 7 is replaced with its D-stereoisomer. This substitution is critical for increased receptor potency and dramatically extended biological half-life, as D-amino acid residues resist enzymatic degradation by endopeptidases that rapidly cleave natural α-MSH.

§ 03 Mechanism of Action

Melanotan 1 acts as a full agonist at the melanocortin 1 receptor (MC1R), a G protein-coupled receptor (GPCR) expressed predominantly on melanocytes, keratinocytes, Langerhans cells, and various immune cell populations. Activation of MC1R by MT-1 initiates a well-characterized intracellular signaling cascade with multiple downstream consequences of research interest.

Upon binding MC1R, MT-1 activates the associated Gαs protein, stimulating adenylyl cyclase activity and increasing intracellular cyclic adenosine monophosphate (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP response element-binding protein). Phosphorylated CREB then upregulates expression of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte identity and function.

MITF activation drives transcription of melanogenic enzymes — most critically tyrosinase, TRP-1 (tyrosinase-related protein 1), and TRP-2 — which catalyze the conversion of tyrosine through DOPA and dopaquinone to eumelanin. Research in melanocyte cell models demonstrates that MT-1 stimulation selectively promotes the eumelanin (brown/black pigment) pathway over the pheomelanin (red/yellow pigment) pathway, a distinction of particular interest in photoprotection and photobiology research.

Beyond melanogenesis, melanocortin receptors have been documented in diverse immune and inflammatory cell populations. Research in macrophage and dendritic cell models has investigated MC1R-mediated anti-inflammatory effects, including modulation of NF-κB signaling and cytokine production (IL-1β, TNF-α). These studies position MT-1 and related melanocortin analogs as research tools for inflammatory pathway investigation — independent of their melanogenic activity.

A key feature distinguishing MT-1 from MT-2 in research contexts is its receptor selectivity. MT-1 (afamelanotide) demonstrates high selectivity for MC1R over other melanocortin receptor subtypes (MC3R, MC4R, MC5R). This selectivity makes it a useful pharmacological probe for dissecting MC1R-specific signaling pathways without the confounding activity at MC4R — which mediates appetite, energy balance, and sexual function through separate pathways — that characterizes MT-2.

§ 04 Melanotan 1 vs Melanotan 2: Key Differences

A frequent question in research sourcing is the distinction between Melanotan 1 (MT-1) and Melanotan 2 (MT-2). While both are synthetic melanocortin analogs descended from α-MSH research, they differ substantially in structure, receptor selectivity, and research application.

§ 05 Published Research Findings

Melanotan 1 (afamelanotide) has been the subject of substantial published research, primarily in the contexts of melanocyte biology, UV photoprotection models, and melanocortin receptor pharmacology. The following summarizes key research areas — all in the context of in vitro cell studies, animal models, or clinical research conducted in regulated settings.

Cell-based studies in human melanocyte cultures have consistently demonstrated that afamelanotide (MT-1) stimulates MC1R-mediated cAMP production at low nanomolar concentrations, with EC50 values substantially lower than native α-MSH. This potency enhancement is attributable to the D-Phe⁷ substitution, which confers greater receptor affinity. Downstream, MITF upregulation and tyrosinase activity increases in MT-1-treated melanocyte cultures have been documented across multiple laboratories, with eumelanin content measurements confirming pigmentation pathway activation.

Animal model research has examined afamelanotide’s capacity to upregulate constitutive eumelanin levels prior to UV exposure, modeling a “pre-tanning” photoprotection hypothesis. Studies in murine models demonstrated reduced UV-induced DNA damage markers (cyclobutane pyrimidine dimers) in skin with elevated eumelanin content. These findings positioned afamelanotide as a research tool for studying eumelanin’s role in DNA photodamage prevention — distinct from sunscreen-based photoprotection mechanisms.

Afamelanotide (branded as Scenesse®) received regulatory approval in the EU (2014) and subsequently in Australia and the USA for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) — a rare genetic disorder causing extreme photosensitivity. This regulatory pathway was based on controlled clinical trials demonstrating extended pain-free sun exposure in EPP patients. This application is the only FDA/EMA-approved clinical use of afamelanotide and is distinct from any research use of MT-1 peptide vials. Research-grade MT-1 purchased from BioLongevity Labs is not equivalent to pharmaceutical-grade Scenesse® and is not for human use.

Independent of melanogenesis, published studies in macrophage and monocyte cell models have investigated α-MSH and afamelanotide’s anti-inflammatory properties. MC1R activation in these models has been associated with reduced secretion of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, via NF-κB pathway modulation. This line of research positions melanocortin agonists as tools for studying innate immune regulation — an active area of melanocortin receptor biology beyond skin pigmentation.

§ 06 Melanotan 1 Sourcing Guide

Researchers seeking to buy Melanotan 1 for in vitro work or laboratory research should be aware that not all sources of MT-1 peptide meet the analytical standards required for reliable, reproducible data. The research peptide market includes a broad range of suppliers with highly variable quality practices — making vendor evaluation a critical step before placing an order.

§ 07 Understanding MT-1 Quality Standards

Analytical quality of research-grade Melanotan 1 peptide is directly relevant to the reliability of experimental results. A peptide preparation at 90% purity contains 10% other species — which may include truncation sequences, deletion analogs, oxidized variants, or aggregates — each of which could produce confounding signals in sensitive biological assays.

High-Performance Liquid Chromatography with UV detection (typically at 220nm for peptide bonds and 280nm for aromatic residues) is the primary method for determining MT-1 purity. A well-resolved chromatogram for a high-purity MT-1 preparation shows a single dominant peak corresponding to the intact 13-amino acid sequence, with all minor peaks summing to less than 1% of total area. Researchers should examine the actual chromatogram image in the COA — not just the stated percentage — to verify peak shape and resolution.

Liquid Chromatography–Mass Spectrometry (LC-MS) confirms that the material in the vial is actually Melanotan 1 (afamelanotide) and not a related analog or substituted compound. The expected [M+H]⁺ ion for MT-1 is approximately m/z 824.0 (doubly charged) or m/z 549.7 (triply charged), from a parent mass of ~1646.85 Da. A COA that does not include LC-MS data should be considered incomplete for research purposes.

For researchers using MT-1 in immune cell models — macrophages, dendritic cells, or peripheral blood mononuclear cells — endotoxin testing is not optional. Lipopolysaccharide (LPS) contamination from bacterial cell walls during peptide synthesis is a well-documented source of artifact in inflammatory cytokine assays. Endotoxin concentrations as low as 0.1 EU/mL can trigger TLR4-mediated responses that overwhelm or mask peptide-specific signaling. Confirm that the COA includes an endotoxin result (EU/mg) from the LAL assay.

§ 08 Reconstitution Notes for MT-1

Melanotan 1 is supplied as a lyophilized powder. Reconstitution should follow standard peptide protocols with attention to MT-1-specific solubility characteristics.

• Recommended solvent: 0.1% acetic acid in sterile water, or bacteriostatic water (BAC water). MT-1 dissolves readily in mildly acidic aqueous solutions. Avoid strongly alkaline conditions which may cause racemization at the D-Phe⁷ position.
• Reconstitution technique: Inject solvent gently against the inner vial wall; allow to wet the lyophilized cake, then gently swirl. Do not vortex — mechanical shear can promote peptide aggregation.
• Working concentration: For cell-based assays, stock solutions of 1–5 mg/mL are typical, with experimental concentrations in the nanomolar range (1–100 nM) for receptor-level studies. Consult primary literature for your specific assay system.
• Aliquoting: Pre-aliquot reconstituted stock into single-use volumes before freezing. Each freeze-thaw cycle degrades peptide integrity — limit to fewer than 3 cycles per aliquot.
• Storage after reconstitution: Reconstituted MT-1 in BAC water is stable at 4°C for up to 2 weeks. For longer storage, aliquots should be kept at −80°C. Protect from light at all stages — aromatic residues (Tyr, Trp, Phe) are photosensitive.